Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations.
about
The Production Processes and Biological Effects of Intravenous ImmunoglobulinImmune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodiesA differential concentration-dependent effect of IVIg on neutrophil functions: relevance for anti-microbial and anti-inflammatory mechanisms.Mechanisms of action of intravenous immunoglobulins.IVIG regulates the survival of human but not mouse neutrophils.On the dark side of therapies with immunoglobulin concentrates: the adverse eventsProtection from experimental autoimmune encephalomyelitis by polyclonal IgG requires adjuvant-induced inflammation.The clinical significance of autoantibodies in gastrointestinal malignancies: an overview.Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL.FAS system deregulation in T-cell lymphoblastic lymphomaReview: intravenous immunoglobulin and B cells: when the product regulates the producer.Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered?Clinical Use and Therapeutic Potential of IVIG/SCIG, Plasma-Derived IgA or IgM, and Other Alternative Immunoglobulin Preparations.Intravenous immunoglobulin: pharmacological properties and use in polyneuropathies.Dose-related regulatory effect of intravenous immunoglobulin on dendritic cells-mediated immune response.Effect of intravenous immunoglobulin administration on erythrocyte and leucocyte parameters.Isolation of Antibodies from Human Plasma, Saliva, Breast Milk, and Gastrointestinal Fluid.Intravenous Immunoglobulins in Autoimmune and Inflammatory Diseases: A Mechanistic Perspective
P2860
Q26752540-B78DBD17-05F1-4BEE-A52A-0FFB5D8A8F5FQ28069362-94721A08-66BF-4DEB-BC14-AF367AF4F0E6Q31040502-22CE1215-784E-42A6-A705-38D13C1DD6E6Q33389428-92D163FE-4CF6-426F-BA30-0382CA0DB8D0Q33683531-A82104E9-2606-424C-BAE8-4406CB8BAF5BQ35053458-338F9DB5-9C46-4634-AC13-3B88E7E03D72Q36592223-A2E00EA2-2EF6-4BD8-8484-008001B49EBFQ36764924-94D26569-AE07-4A4D-A9B4-FD7D0DEAF3E4Q36958361-EB0FD11D-09BD-475D-821E-E17509722C46Q37680225-0FD94F0C-0FEB-42CA-B38B-330077ADA383Q38258905-2160DAD4-2789-4624-882A-54B405E39EBEQ38283308-916BA8D2-BB39-453C-A8BC-9596DB983520Q38820288-115D1AE5-E750-40B8-AA7F-459024192D81Q38900642-447D67B2-D184-4035-AE8C-D253B6A0C7BDQ42251007-EC76AD49-1D7B-4CB2-8001-4FFB20C814AFQ50113680-62533B4E-5533-4780-AFD8-F27F26C5C913Q53726982-881342F0-48D1-4D5B-95D5-A4D865D2962FQ58864646-DA9B41BD-E5EA-4ADC-B080-8EC3B933513A
P2860
Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Concurrent presence of agonist ...... n intravenous Ig preparations.
@en
Concurrent presence of agonist ...... n intravenous Ig preparations.
@nl
type
label
Concurrent presence of agonist ...... n intravenous Ig preparations.
@en
Concurrent presence of agonist ...... n intravenous Ig preparations.
@nl
prefLabel
Concurrent presence of agonist ...... n intravenous Ig preparations.
@en
Concurrent presence of agonist ...... n intravenous Ig preparations.
@nl
P1476
Concurrent presence of agonist ...... n intravenous Ig preparations.
@en
P2093
Frank Altznauer
Peter Späth
P304
P356
10.1016/J.JACI.2003.09.045
P407
P577
2003-12-01T00:00:00Z